Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis

Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis

Background. Immune checkpoint inhibitors (ICIs) have been evaluated as neoadjuvant treatment in urothelial carcinoma (UC) patients, with these agents reporting encouraging pathologic complete response (pCR) rates. Herein, we performed a systematic review and meta-analysis aimed at evaluating the inc...

Full description

Bibliographic Details
Main Authors:	Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Gennaro Palmiotti, Francesco Massari
Format:	Article
Language:	English
Published:	MDPI AG 2022-02-01
Series:	Journal of Clinical Medicine
Subjects:	immunotherapy immune checkpoint inhibitors pembrolizumab atezolizumab urothelial carcinoma neoadjuvant
Online Access:	https://www.mdpi.com/2077-0383/11/4/1038

Similar Items

Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis
by: Alessandro Rizzo, et al.
Published: (2022-06-01)

The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy among Patients with Urothelial Carcinoma: A Meta-Analysis
by: Alessandro Rizzo, et al.
Published: (2022-05-01)

Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy—Real-World Clinical Impressions and Comparative Review of the Literature
by: Christian Fuhrmann, et al.
Published: (2020-05-01)

Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward
by: Alessandro Rizzo, et al.
Published: (2022-04-01)

PD-L1 Testing in Urothelial Carcinoma: Analysis of a Series of 1401 Cases Using Both the 22C3 and SP142 Assays
by: Harriet Evans, et al.
Published: (2022-04-01)

Case Report: Good responsiveness of metastatic sarcomatoid urothelial carcinoma with chondrosarcomatous differentiation to immune checkpoint inhibitor after radical surgery and chemotherapy [version 2; peer review: 2 approved]
by: Ho Kyung Seo, et al.
Published: (2022-03-01)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
by: Nobutaka Nishimura, et al.
Published: (2022-09-01)

Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney
by: Jun Kamei, et al.
Published: (2022-05-01)

Complete Pathological Response to Neoadjuvant Pembrolizumab in a Patient With Chemoresistant Upper Urinary Tract Urothelial Carcinoma: A Case Report
by: Daiki Ikarashi, et al.
Published: (2020-09-01)

Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer
by: Maximilian Marhold, et al.
Published: (2023-12-01)

IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab
by: Toru Sakatani, et al.
Published: (2022-01-01)

Neoadjuvant Immunotherapy: The Next Gold Standard Before Radical Surgery for Urothelial Cancer
by: Daniele Raggi, et al.
Published: (2021-08-01)

Trial watch: Immune checkpoint blockers for cancer therapy
by: Claire Vanpouille-Box, et al.
Published: (2017-11-01)

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
by: Sarabjot Pabla, et al.
Published: (2019-02-01)

PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis
by: Muhammad Khan, et al.
Published: (2023-03-01)

Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review
by: Nabil E. Omar, et al.
Published: (2020-10-01)

Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?
by: Kartik Sehgal, et al.
Published: (2020-06-01)

Thyroid disorders induced by immune checkpoint inhibitors therapy of malignant tumors
by: Anastasiya A. Glibka, et al.
Published: (2022-10-01)

Neoadjuvant chemotherapy improves survival rate in advanced urothelial carcinoma
by: Chia-Chun Tsai, et al.
Published: (2013-04-01)

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer
by: Randy F. Sweis, et al.
Published: (2018-04-01)

Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors
by: Jean-Michel Lavoie, et al.
Published: (2021-11-01)

A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome
by: Ryosuke Oki, et al.
Published: (2023-01-01)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
by: Inokuchi J, et al.
Published: (2019-05-01)

A unique case of protein-losing enteropathy in the setting of immune checkpoint inhibition case report
by: Ezra Bernstein, et al.
Published: (2023-09-01)

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
by: Jeffrey M. Conroy, et al.
Published: (2019-01-01)

Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes
by: Dmitrii Shek, et al.
Published: (2021-08-01)

Predictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysis
by: Hazem E. El-Osta, et al.
Published: (2019-12-01)

Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma
by: Kyotaro Fukuta, et al.
Published: (2021-09-01)

Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma
by: Veronica Mollica, et al.
Published: (2020-06-01)

Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma
by: Nataliya Mar, et al.
Published: (2023-05-01)

Immunotherapy in Urothelial Cancer: Stop When Achieving a Response, Restart upon Disease Progression
by: Youssra Salhi, et al.
Published: (2023-07-01)

Anti-PD-L1 monoclonal antibody for the management of chronic disseminated intravascular coagulation secondary to a urothelial carcinoma: a case report
by: Silvia Maiorano, et al.
Published: (2022-03-01)

Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Minireview of Current Clinical Guidelines
by: Saralinh Trinh, et al.
Published: (2019-01-01)

Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors
by: Maria Lucia Iacovino, et al.
Published: (2022-01-01)

Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis
by: Xueyan Liang, et al.
Published: (2023-05-01)

Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma
by: Hsiao-Ling Chen, et al.
Published: (2020-12-01)

Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single‐center analysis in Japan
by: Motohiro Fujiwara, et al.
Published: (2021-12-01)

Case Report: Neoadjuvant immunotherapy with pembrolizumab alone for bilateral upper tract urothelial carcinoma is a feasible strategy for kidney sparing and avoidance of hemodialysis
by: Wai-Nga Chan, et al.
Published: (2022-09-01)

The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival
by: Elise F. Nassif, et al.
Published: (2021-01-01)

A case of acute lymphocytic gastritis related to treatment with pembrolizumab for metastatic urothelial carcinoma
by: Yousuke Fukiishi, et al.
Published: (2023-03-01)